Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79770 | 1.00 | PTGS1 (0.50) | PTGS1PTGS2ALOX5TP53TDP1 | |
| SCHEMBL17485263 | 0.85 | NFE2L2 (0.41) | FBP1NPC1MAOAMAOBIDO1 | |
| SCHEMBL8442069 | 0.82 | TP53 (0.52) | PTGS1PTGS2ALOX5TP53TDP1 | |
| SCHEMBL19227545 | 0.82 | TP53 (0.52) | PTGS1PTGS2ALOX5TP53TDP1 | |
| SCHEMBL8442071 | 0.82 | TP53 (0.52) | PTGS1PTGS2ALOX5TP53TDP1 | |
| SCHEMBL1795132 | 0.80 | PTGS1 (0.69) | PTGS1PTGS2ALOX5TP53TDP1 | |
| SCHEMBL1795130 | 0.80 | PTGS1 (0.69) | PTGS1PTGS2ALOX5TP53TDP1 | |
| SCHEMBL21847980 | 0.80 | PTGS1 (0.69) | PTGS1PTGS2ALOX5TP53TDP1 | |
| SCHEMBL81659 | 0.80 | PTGS1 (0.55) | PTGS1PTGS2ALOX5TP53TDP1 | |
| SCHEMBL2771432 | 0.80 | PTGS1 (0.50) | PTGS1PTGS2ALOX5TP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10583112-B2 | Benzo[b]furans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-05-23 | — | — | US | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| CN-102838625-A | Tetrahydropyridothiazole compounds, preparation method thereof, pharmaceutical composition containing same and application thereof | SHANGHAI INST MATERIA MEDICA | 2012-12-26 | — | — | CN | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-1967509-B1 | METHOD FOR PRODUCING PRIMARY AMINE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2010-04-14 | — | — | EP | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-7652170-B2 | Method for producing primary amine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090287023-A1 | METHOD FOR PRODUCING PRIMARY AMINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-1967509-A1 | METHOD FOR PRODUCING PRIMARY AMINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-09-10 | — | — | EP | disclosed |
| EP-0657163-B1 | ANTITUSSIVE | TORAY INDUSTRIES (JP) | 1998-10-14 | — | — | EP | disclosed |
| US-5739145-A | MORPHINAN DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0657163-A1 | ANTITUSSIVE | TORAY INDUSTRIES, INC. (JP) | 1995-06-14 | — | — | EP | disclosed |
| EP-0347766-B1 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | THOMAE GMBH DR K (DE) | 1994-05-25 | — | — | EP | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0415729-A2 | Vinylphenyl compound, process for the production thereof, polymerizable composition containing same, and crosslinked polymer formed therefrom | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1991-03-06 | — | — | EP | disclosed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10583112-B2 | Benzo[b]furans as bromodomain inhibitors | BRD4, BRD3, BRD2 | PTGS1 476/4885PTGS2 733/4885ALOX5 2105/4885 |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | PTGS1 476/4885PTGS2 733/4885ALOX5 2105/4885 |
| US-20090287023-A1 | METHOD FOR PRODUCING PRIMARY AMINE COMPOUND | HRH3, HRH4, C5 | PTGS1 1989/4885PTGS2 2781/4885ALOX5 203/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | PTGS1 3602/4885PTGS2 4185/4885ALOX5 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.